Cronos Group Inc (OTCMKTS:PRMCF) shares have been exploding higher in a truly parabolic ascent that has dominated the action in this stock over the past several weeks. During that stretch, we have seen this stock rise as much as 120% in a straight line. This action has been part of a larger move higher in the cannabis space, but also reflects some clear catalysts working for the name as a standout positive play within that context — one that has been clicking with massive top-line sales growth as well.
The latest from the company comes in the form of its announcement that its first shipment to G. Pohl-Boskamp GmbH & Co. KG of Peace Naturals branded products is now available for sale across retail locations throughout Germany. Peace is a wholly-owned licensed producer operated by Cronos, and Pohl-Boskamp is an international pharmaceutical manufacturer with distribution into over 12,000 pharmacies in Germany.
Cronos Group Inc (OTCMKTS:PRMCF) trumpets itself as a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers (“LPs”) regulated within Health Canada’s Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) and holds a portfolio of minority investments in other Licensed Producers.
The Company’s flagship LPs, Peace Naturals Project Inc. (Ontario) and Original BC Ltd. (British Columbia), are collectively situated on over 125 acres of agricultural, licensed land.
Cronos Group is focused on building an international iconic brand portfolio, providing patients with personalized care, and creating value for our shareholders.
Find out when $PRMCF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, the company just announced that it has made its first shipment to G. Pohl-Boskamp GmbH & Co. KG of Peace Naturals branded products, which are now available for sale across retail locations throughout Germany.
According to the release, “with over 82 million people, Germany is the largest federally legal cannabis market in the world, and Pohl-Boskamp’s distribution network provides Cronos access to patients with insurance coverage for medicinal cannabis.”
“This marks a key milestone for Cronos by solidifying the largest international distribution platform in the industry and providing an unprecedented supply of high-quality medical cannabis products to German patients,” said Mike Gorenstein, CEO of Cronos.
According to our research, Pohl-Boskamp is a privately-owned business that has been active in the international pharmaceutical market for 182 years with commercialized products in more than 45 countries. Through close collaboration with its partners abroad, Pohl-Boskamp focuses on developing and marketing products that positively impact patients’ quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders, and dermatology.
This type of commerce is a huge positive for PRMCF because it implies international expansion. We have consistently seen a premium placed on companies that are able to latch onto deals that grant them geographic diversity because it carries the implications of protection against a sudden shift in the legislative reality underpinning the space. For investors, it means peace of mind. For the company, it clearly means another aggressive move that pushes the ROI equation outward. And in a high-growth market space, that is likely a step that gets rewarded by the market.
We’ve witnessed a bit more than 130% piled on for shareholders of the stock during the trailing month. The situation may be worth watching. PRMCF has evidenced sudden upward volatility on many prior occasions. Moreover, the stock has registered increased average transaction volume recently, with the past month seeing topping 410% above the average volume levels in play in this stock over the longer term.
Earning a current market cap value of $1111.3M, PRMCF has a significant war chest ($16.5M) of cash on the books, which must be weighed relative to about $869K in total current liabilities. PRMCF is pulling in trailing 12-month revenues of $5.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 1840.4%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $PRMCF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PRMCF, either long or short, and we have not been compensated for this article.